Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SINGAPORE EXCHANGE  >  Luye Pharma Group Ltd    LUYE   BMG5722Z1014

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

LUYE PHRM : Exercise Of The Call Option By Luye Biotech (Singapore) Pte Ltd Under The Investment Agreement To Acquire All The Shares Held By Biomedical Sciences Investment Fund Pte Ltd In The Issued Share Capital Of A-Bio Pharma Pte Ltd

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/25/2011 | 12:35pm CEST

LUYE PHARMA GROUP LTD.

(INCORPORATED IN BERMUDA)

EXERCISE OF THE CALL OPTION BY LUYE BIOTECH (SINGAPORE) PTE LTD UNDER THE INVESTMENT AGREEMENT TO ACQUIRE ALL THE SHARES HELD BY BIOMEDICAL SCIENCES INVESTMENT FUND PTE LTD IN THE ISSUED SHARECAPITAL OF A-BIO PHARMA PTE LTD

Where capitalised terms are used in this announcement and not otherwise defined, such capitalised terms shall bear the same meanings as ascribed to them in the Company?s announcement dated

30 July 2010 in relation to the Strategic Investment in A-Bio Pharma Pte Ltd by Luye-Biotech

(Singapore) Pte Ltd.

The Board of Directors of Luye Pharma Group Ltd. (?Luye? or ?the Company?) is pleased to announce that Luye Biotech, a wholly-owned subsidiary of the Company, has exercised the Call Option under the Investment Agreement to acquire all of BMSIF?s shares comprising (i) one (1) ordinary share and (ii) 2,500,000 preference shares (Series B Preferred Shares) (collectively known as the ?Call Option Shares?) in A-Bio Pharma Pte Ltd (?A-Bio?) at a Option Consideration of S$2,750,000.

When the acquisition is completed, the Company will own 100% of the entire issued share capital of A-Bio through another wholly-owned subsidiary, Shandong Luye Pharmaceutical Co. Ltd.

The Option Consideration will funded by internal resources and is not expected to have any material impact on the net tangible assets per share and earnings per share of the Company for the current financial year ending 31 December 2011.

None of the Directors or controlling shareholders has any interest, directly or indirectly, in the transaction.

By Order of the Board

Liu Dianbo

Executive Chairman

Date: 25 July 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LUYE PHARMA GROUP LTD
08/11 LUYE PHARMA : Boosts Its Product Portfolio in Biomedicine by Acquiring 2 Biologi..
08/05 LUYE PHARMA : Connected transaction in relation to the acquisition of two biolog..
07/17 LUYE PHARMA : Monthly Return of Equity Issuer on Movements in Securities for the..
06/17 LUYE PHARMA : Poll results of annual general meeting held on 13 june 2017
06/17 LUYE PHARMA : Typhoon arrangement for the annual general meeting to be held on 1..
06/09 LUYE PHARMA : Purchase of Shares under The Luye Pharma Share Award Scheme
05/16 LUYE PHARMA : Paclitaxel Injection Market 2017 - Hospira, Haiyao, Chuntch, Taj A..
05/08 LUYE PHARMA : Green Leaf Group Co., Ltd. changed its name to notice
05/02 LUYE PHARMA : Form of proxy for use at annual general meeting to be held on 13 j..
05/02 LUYE PHARMA : Proposals for general mandates to issue shares and repurchase shar..
More news
Financials ( CNY)
Sales 2017 3 621 M
EBIT 2017 1 204 M
Net income 2017 1 056 M
Finance 2017 849 M
Yield 2017 2,22%
P/E ratio 2017 11,90
P/E ratio 2018 10,30
EV / Sales 2017 3,22x
EV / Sales 2018 2,78x
Capitalization 12 514 M
Chart LUYE PHARMA GROUP LTD
Duration : Period :
Luye Pharma Group Ltd Technical Analysis Chart | LUYE | BMG5722Z1014 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 5,36  CNY
Spread / Average Target 42%
EPS Revisions
Managers
NameTitle
Dian Bo Liu Executive Chairman & Chief Executive Officer
Yuan Chong Liu Chief Financial Officer
You Xin Li Vice President, Head-Research & Development
Hui Xian Yuan Executive Director
Rong Bing Yang Vice Executive Chairman
Sector and Competitors